logo

TWST

Twist Bioscience·NASDAQ
--
--(--)
--
--(--)
2.21 / 10
Underperform

Corporate fundamentals are assessed as challenging, scoring 2.2/10. Key drawbacks include subpar revenue and current assets turnover, while profit, cash, and gross margin factors show moderate strength. Historical back-tests reveal low to moderate returns across most fundamental metrics, reinforcing a cautious stance on the company's intrinsic value.

Fundamental(2.21)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.89
Score1/3
Weight12.60%
1M Return5.20%
Inventory turnover ratio
Value7.08
Score2/3
Weight-4.78%
1M Return-2.63%
Gross profit margin (%)
Value50.72
Score2/3
Weight3.12%
1M Return1.47%
Profit-MV
Value0.44
Score2/3
Weight18.86%
1M Return7.79%
PB-ROE
Value1.92
Score2/3
Weight26.48%
1M Return10.68%
Current assets turnover ratio
Value1.11
Score1/3
Weight-0.95%
1M Return-0.48%
Fixed assets turnover ratio
Value2.41
Score2/3
Weight0.25%
1M Return0.12%
Asset-MV
Value-0.50
Score1/3
Weight22.87%
1M Return8.74%
Cash-MV
Value0.14
Score2/3
Weight18.89%
1M Return7.73%
Net profit / Total profit (%)
Value100.93
Score2/3
Weight2.67%
1M Return1.28%
Is TWST undervalued or overvalued?
  • TWST scores 2.21/10 on fundamentals and holds a Premium valuation at present. Backed by its -6.57% ROE, -19.56% net margin, -39.42 P/E ratio, 6.62 P/B ratio, and 62.43% earnings growth, these metrics solidify its Underperform investment rating.